NO20033288L - Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer - Google Patents

Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer

Info

Publication number
NO20033288L
NO20033288L NO20033288A NO20033288A NO20033288L NO 20033288 L NO20033288 L NO 20033288L NO 20033288 A NO20033288 A NO 20033288A NO 20033288 A NO20033288 A NO 20033288A NO 20033288 L NO20033288 L NO 20033288L
Authority
NO
Norway
Prior art keywords
phosphodiesterase
inhibitors
aniline derivatives
aniline
derivatives
Prior art date
Application number
NO20033288A
Other languages
English (en)
Other versions
NO20033288D0 (no
NO329548B1 (no
Inventor
Allen Hopper
Richard A Schumacher
Ashok Tehim
Michael De Vivo
Jr William Frederick Brubaker
Ruiping Liu
Hans-Juergen Ernst Hess
Axel Unterbeck
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of NO20033288D0 publication Critical patent/NO20033288D0/no
Publication of NO20033288L publication Critical patent/NO20033288L/no
Publication of NO329548B1 publication Critical patent/NO329548B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/88—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/92—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20033288A 2001-01-22 2003-07-21 Anilinderivater, farmasoytiske preparater som omfatter en slik forbindelse, samt anvendelser av forbindelsene til fremstilling av medikamenter for behandling av kognisjonsforstyrrelser, depresjon eller allergiske eller inflammatoriske sykdommer NO329548B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26265101P 2001-01-22 2001-01-22
US26719601P 2001-02-08 2001-02-08
US30614001P 2001-07-19 2001-07-19
PCT/US2002/001508 WO2002074726A2 (en) 2001-01-22 2002-01-22 Aniline derivatives useful as phosphodiesterase 4 inhibitors

Publications (3)

Publication Number Publication Date
NO20033288D0 NO20033288D0 (no) 2003-07-21
NO20033288L true NO20033288L (no) 2003-09-22
NO329548B1 NO329548B1 (no) 2010-11-08

Family

ID=27401532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033288A NO329548B1 (no) 2001-01-22 2003-07-21 Anilinderivater, farmasoytiske preparater som omfatter en slik forbindelse, samt anvendelser av forbindelsene til fremstilling av medikamenter for behandling av kognisjonsforstyrrelser, depresjon eller allergiske eller inflammatoriske sykdommer

Country Status (24)

Country Link
EP (1) EP1353907A2 (no)
JP (1) JP4223287B2 (no)
KR (1) KR100856622B1 (no)
CN (1) CN100378075C (no)
AU (1) AU2002303078B2 (no)
BG (1) BG108003A (no)
BR (1) BR0206943A (no)
CA (1) CA2435847A1 (no)
CL (1) CL2004001165A1 (no)
CZ (1) CZ20031986A3 (no)
EE (1) EE05362B1 (no)
HK (1) HK1066215A1 (no)
HR (1) HRP20030662A2 (no)
HU (1) HUP0302793A3 (no)
IL (1) IL156958A0 (no)
MA (1) MA25996A1 (no)
MX (1) MXPA03006519A (no)
NO (1) NO329548B1 (no)
NZ (1) NZ527081A (no)
PL (1) PL373301A1 (no)
SK (1) SK9152003A3 (no)
WO (1) WO2002074726A2 (no)
YU (1) YU57603A (no)
ZA (1) ZA200305623B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
ATE437853T1 (de) * 2001-02-14 2009-08-15 Karobio Ab Glucocorticoid-rezeptoren-modulatoren
BR0313000A (pt) 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
NZ537724A (en) * 2002-07-19 2006-10-27 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
BR0315705A (pt) * 2002-11-19 2005-09-06 Memory Pharm Corp Inibidores de fosfodiesterase-4
EP1592419A1 (en) * 2002-11-22 2005-11-09 Merck Frosst Canada & Co. Use of phosphodiesterase-4 inhibitors as enhancers of cognition
US7368472B2 (en) * 2002-12-27 2008-05-06 H. Lundbeck A/S 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CN1984906A (zh) 2004-07-15 2007-06-20 日本烟草产业株式会社 稠合苯甲酰胺化合物和香草素受体1(vr1)活性抑制剂
JP2008518913A (ja) * 2004-10-28 2008-06-05 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子
EA015382B1 (ru) 2005-03-08 2011-08-30 Никомед Гмбх Применение рофлумиласта для лечения сахарного диабета типа 2
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
EP2110375A1 (en) * 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010041449A1 (ja) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Rxr作動性物質を有効成分とする抗アレルギー剤
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
WO2010143169A2 (en) 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
WO2011099305A1 (en) 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
US9550763B2 (en) 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
CN102603676B (zh) * 2012-02-20 2014-02-12 徐江平 一种能避免呕吐反应的磷酸二酯酶4抑制剂
US9376376B2 (en) * 2012-03-14 2016-06-28 Sinochem Corporation Substitute diphenylamine compounds use thereof as antitumor agents
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
US9827237B2 (en) 2013-07-05 2017-11-28 Abivax Compounds useful for treating diseases caused by retroviruses
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09501405A (ja) 1993-05-27 1997-02-10 スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク 抗不整脈用ｎ−置換３−ベンズアゼピンまたはイソキノリン
JPH07206789A (ja) * 1993-09-01 1995-08-08 Taisho Pharmaceut Co Ltd コンブレタスタチン類縁化合物
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) * 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
US6235736B1 (en) * 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DE50011851D1 (de) * 1999-12-18 2006-01-19 Wella Ag 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel

Also Published As

Publication number Publication date
CN100378075C (zh) 2008-04-02
SK9152003A3 (en) 2004-04-06
MXPA03006519A (es) 2004-10-15
JP2005507365A (ja) 2005-03-17
AU2002303078B2 (en) 2007-08-30
ZA200305623B (en) 2005-01-26
NZ527081A (en) 2006-03-31
CL2004001165A1 (es) 2005-04-15
EE05362B1 (et) 2010-12-15
WO2002074726A2 (en) 2002-09-26
YU57603A (sh) 2006-08-17
HUP0302793A3 (en) 2006-01-30
BG108003A (bg) 2004-09-30
CA2435847A1 (en) 2002-09-26
KR100856622B1 (ko) 2008-09-03
EE200300347A (et) 2003-12-15
BR0206943A (pt) 2006-01-24
IL156958A0 (en) 2004-02-08
JP4223287B2 (ja) 2009-02-12
CN1498211A (zh) 2004-05-19
NO20033288D0 (no) 2003-07-21
PL373301A1 (en) 2005-08-22
CZ20031986A3 (cs) 2003-12-17
EP1353907A2 (en) 2003-10-22
NO329548B1 (no) 2010-11-08
HUP0302793A2 (hu) 2003-11-28
HK1066215A1 (en) 2005-03-18
HRP20030662A2 (en) 2005-06-30
MA25996A1 (fr) 2003-12-31
WO2002074726A3 (en) 2003-03-13
KR20040064606A (ko) 2004-07-19

Similar Documents

Publication Publication Date Title
NO20033288L (no) Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
DK1944305T3 (da) Quinolinderivater som phosphodiesteraseinhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DE60234125D1 (de) E inhibitoren
DK1373224T3 (da) Nye spirotricykliske derivater og deres anvendelse som phosphodiesterase 7 inhibitorer
NO20033593L (no) Kinazoliner som MMP-13 inhibitorer
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
DK1370553T3 (da) Rho-kinase-inhibitorer
DK1370552T3 (da) Rho-kinase-inhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK1527050T3 (da) Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
NO20031450L (no) Fumarsyrederivater som NF-kappa B inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
NO20035728D0 (no) Pyrrolopyrimidiner som proteinkinaseinhibitorer
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20040996L (no) Nye forbindelser og sammensetninger som catepsin-inhibitorer
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
DK1651641T3 (da) Nicotinamidderivater egnede som PDE4 inhibitorer
NO20043119L (no) Triazolokinolinderivater som kan anvendes som adenosinreseptorligander

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees